{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"12.4","value":"4.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.7","upperLimit":"67.6","value":"54.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"title":"Core Week 17 n=57"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.4","upperLimit":"81.8","value":"68.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"Core Week 35 n=45"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.1","upperLimit":"97.1","value":"86.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Ext Week 43 n=22"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.1","upperLimit":"93.2","value":"76.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"Ext Week 67 n=17"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.6","upperLimit":"96.4","value":"83.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"title":"Ext Week 91 n=18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.0","upperLimit":"99.8","value":"92.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Ext Week 115 n=13"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.0","upperLimit":"97.2","value":"77.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Ext Week 139 n=9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.9","upperLimit":"99.6","value":"83.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Ext Week 163 n=6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.8","upperLimit":"100.0","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Ext Week 187 n=4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.4","upperLimit":"99.2","value":"66.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Ext Week 211 n=3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.2","upperLimit":"100.0","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Ext Week 235 n=3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"Actual mean value of mUFC at each scheduled visit was determined from two 24-hour urine collections collected on two consecutive days that occurred before the visit when UFC was measured.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pasireotide montherapy (0.6 mg bid to 0.9 mg bid) was administered until the biochemical control was achieved and if not achieved, a combination was administered: pasireotide (0.9 mg bid) + cabergoline (0.5 QD to 1 mg QD). Patients were able to add cabergoline at anytime during core and extension","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"Full analysis set. The data beyond Week 139 should be interpreted with caution given that small number of subjects were monitored","reportingStatus":"POSTED","timeFrame":"Baseline up to week 235","title":"Percentage of Participants Who Attain mUFC ≤ 1.0 x ULN or Have at Least 50% Reduction From Baseline in mUFC","type":"SECONDARY","unitOfMeasure":"percentage of responders"}